Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2009, Article ID 681482, 10 pages
http://dx.doi.org/10.1155/2009/681482
Review Article

Mizoribine: A New Approach in the Treatment of Renal Disease

Department of Pediatrics, Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima City, Fukushima 960-1295, Japan

Received 23 April 2009; Revised 6 August 2009; Accepted 16 September 2009

Academic Editor: Chaim Putterman

Copyright © 2009 Yukihiko Kawasaki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Mizuno, M. Tsujino, M. Takada, M. Hayashi, and K. Atsumi, “Studies on bredinin. I. Isolation, characterization and biological properties,” Journal of Antibiotics, vol. 27, no. 10, pp. 775–782, 1974. View at Google Scholar · View at Scopus
  2. K. Kamata, M. Okubo, E. Ishigamori et al., “Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals,” Transplantation, vol. 35, no. 2, pp. 144–149, 1983. View at Google Scholar · View at Scopus
  3. Y. Ichikawa, H. Ihara, and S. Takahara, “The immunosuppressive mode of action of mizoribine,” Transplantation, vol. 38, no. 3, pp. 262–267, 1984. View at Google Scholar · View at Scopus
  4. H. Ishikawa, “Mizoribine and mycophenolate mofetil,” Current Medicinal Chemistry, vol. 6, no. 7, pp. 575–597, 1999. View at Google Scholar · View at Scopus
  5. T. Hamasaki, M. Mori, Y. Kinoshita, T. Saeki, and T. Sakano, “Mizoribine in steroid-dependent nephrotic syndrome of childhood,” Pediatric Nephrology, vol. 11, no. 5, pp. 625–627, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Sonda, K. Takahashi, K. Tanabe et al., “Clinical pharmacokinetic study of mizoribine in renal transplantation patients,” Transplantation Proceedings, vol. 28, no. 6, pp. 3643–3648, 1996. View at Google Scholar · View at Scopus
  7. A. C. Allison, T. Hovi, R. W. E. Watts, and A. D. B. Webster, “Immunological observations on patients with Lesch Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation,” The Lancet, vol. 2, no. 7946, pp. 1179–1183, 1975. View at Google Scholar · View at Scopus
  8. A. C. Allison, T. Hovi, R. W. Watts, and A. D. Webster, “The role of de novo purine synthesis in lymphocyte transformation,” Ciba Foundation Symposium, no. 48, pp. 207–224, 1977. View at Google Scholar · View at Scopus
  9. T. Hovi, A. C. Allison, K. Raivio, and A. Vaheri, “Purine metabolism and control of cell proliferation,” Ciba Foundation Symposium, no. 48, pp. 225–248, 1977. View at Google Scholar · View at Scopus
  10. K. Sakaguchi, M. Tsujino, M. Yoshizawa, K. Mizuno, and K. Hayano, “Action of bredinin on mammalian cells,” Cancer Research, vol. 35, no. 7, pp. 1643–1648, 1975. View at Google Scholar · View at Scopus
  11. K. Sakaguchi, M. Tsujino, K. Mizuno, K. Hayano, and N. Ishida, “Effect of bredinin and its aglycone on L5178Y cells,” Journal of Antibiotics, vol. 28, no. 10, pp. 798–803, 1975. View at Google Scholar · View at Scopus
  12. G. A. LePage and J. P. Whitecar Jr., “Pharmacology of 6-thioguanine in man,” Cancer Research, vol. 31, no. 11, pp. 1627–1631, 1971. View at Google Scholar · View at Scopus
  13. K. Sakaguchi, M. Tsujino, M. Hayashi, K. Kawai, K. Mizuno, and K. Hayano, “Mode of action of bredinin with guanylic acid on L5178Y mouse leukemia cells,” Journal of Antibiotics, vol. 29, no. 12, pp. 1320–1327, 1976. View at Google Scholar · View at Scopus
  14. H. Koyama and M. Tsuji, “Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells,” Biochemical Pharmacology, vol. 32, no. 23, pp. 3547–3553, 1983. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Kusumi, M. Tsuda, T. Katsunuma, and M. Yamamura, “Dual inhibitory effect of bredinin,” Cell Biochemistry and Function, vol. 7, no. 3, pp. 201–204, 1989. View at Google Scholar · View at Scopus
  16. L. A. Turka, J. Dayton, G. Sinclair, C. B. Thompson, and B. S. Mitchell, “Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine,” Journal of Clinical Investigation, vol. 87, no. 3, pp. 940–948, 1991. View at Google Scholar · View at Scopus
  17. J. S. Dayton, L. A. Turka, C. B. Thompson, and B. S. Mitchell, “Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism,” Molecular Pharmacology, vol. 41, no. 4, pp. 671–676, 1992. View at Google Scholar · View at Scopus
  18. H. Itoh, A. Komatsuda, H. Wakui, A. B. Miura, and Y. Tashima, “Mammalian HSP60 is a major target for an immunosuppressant mizoribine,” Journal of Biological Chemistry, vol. 274, no. 49, pp. 35147–35151, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Takahashi, H. Wakui, J.-A. Gustafsson, J. Zilliacus, and H. Itoh, “Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein,” Biochemical and Biophysical Research Communications, vol. 274, no. 1, pp. 87–92, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. J. Murase, K. Mizuno, K. Kawai et al., “Absorption, distribution, metabolism and excretion of bredinin in rats,” Pharmacometrics, vol. 15, no. 5, pp. 829–835, 1978 (Japanese). View at Google Scholar · View at Scopus
  21. R. Kusaba, O. Otubo, T. Inou, M. Tsujino, and H. Ishikawa, “Studies on pharmacokinetics of bredinin,” Japanese Journal of Transplantation, vol. 17, supplement, p. 585, 1982 (Japanese). View at Google Scholar
  22. K. Takada, S. Muranishi, S. Asada et al., “Clinical pharmacokinetic study of bredinin in renal transplant patients,” Transplantation, vol. 17, supplement, p. 595, 1982 (Japanese). View at Google Scholar
  23. D. Stypinski, M. Obaidi, M. Combs, M. Weber, A. J. Stewart, and H. Ishikawa, “Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers,” British Journal of Clinical Pharmacology, vol. 63, no. 4, pp. 459–468, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. Y. Kawasaki, J. Suzuki, A. Takahashi, M. Isome, R. Nozawa, and H. Suzuki, “Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome,” Pediatric Nephrology, vol. 20, no. 1, pp. 96–98, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. Y. Kawasaki, M. Hosoya, S. Kobayashi et al., “Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome,” Nephrology Dialysis Transplantation, vol. 20, no. 10, pp. 2243–2247, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. Y. Kawasaki, K. Takano, M. Isome et al., “Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome,” Journal of Nephrology, vol. 20, no. 1, pp. 52–56, 2007. View at Google Scholar · View at Scopus
  27. K. Tanabe, T. Tokumoto, N. Ishikawa et al., “Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression,” Transplantation Proceedings, vol. 31, no. 7, pp. 2877–2879, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Kaneko, R. Nagaoka, Y. Ohtomo, and Y. Yamashiro, “Mizoribine for childhood IgA nephropathy,” Nephron, vol. 83, no. 4, pp. 376–377, 1999. View at Google Scholar · View at Scopus
  29. R. Nagaoka, K. Kaneko, Y. Ohtomo, and Y. Yamashiro, “Mizoribine treatment for childhood IgA nephropathy,” Pediatrics International, vol. 44, no. 2, pp. 217–223, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Kawasaki, J. Suzuki, N. Sakai et al., “Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy,” American Journal of Nephrology, vol. 24, no. 1, pp. 147–153, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. N. Yoshikawa, K. Nakanishi, K. Ishikura, H. Hataya, K. Iijima, and M. Honda, “Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study,” Pediatric Nephrology, vol. 23, no. 5, pp. 757–763, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. S. Koshikawa, M. Sato, M. Narita, N. Sakai, and M. Nakajima, “Clinical evalution of an immunosuppressive drug, mizoribine (HE-69) on steroid-resistant nephritic syndrome-A multicenter double-blind comparison study with placebo,” Kidney and Dialysis, vol. 34, p. 631, 1993 (Japanese). View at Google Scholar
  33. K. Yoshioka, Y. Ohashi, T. Sakai et al., “A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome,” Kidney International, vol. 58, no. 1, pp. 317–324, 2000. View at Publisher · View at Google Scholar · View at PubMed
  34. Y. Ohtomo, S.-I. Fujinaga, M. Takada et al., “High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity,” Pediatric Nephrology, vol. 20, no. 12, pp. 1744–1749, 2005. View at Publisher · View at Google Scholar · View at PubMed
  35. W. Yumura, S. Suganuma, K. Uchida et al., “Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis,” Clinical Nephrology, vol. 64, no. 1, pp. 28–34, 2005. View at Google Scholar
  36. H. Tanaka, K. Tsugawa, K. Suzuki, T. Nakahata, and E. Ito, “Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis,” Pediatric Nephrology, vol. 21, no. 7, pp. 962–966, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. H. Tanaka, K. Tsugawa, E. Oki, K. Suzuki, and E. Ito, “Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients,” Clinical Rheumatology, vol. 27, no. 1, pp. 85–89, 2008. View at Publisher · View at Google Scholar · View at PubMed
  38. K. Nozu, K. Iijima, I. Kamioka et al., “High-dose mizoribine treatment for adolescents with systemic lupus erythematosus,” Pediatrics International, vol. 48, no. 2, pp. 152–157, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. T. Imaizumi, Y. Kawasaki, H. Matsuura et al., “Efficacy of steroid pulse, plasmapheresis, and mizoribine in a patient with focal segmental glomerulosclerosis,” Pediatric Nephrology, vol. 22, no. 8, pp. 1215–1218, 2007. View at Google Scholar
  40. K. Hirayama, M. Kobayashi, Y. Hashimoto et al., “Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis,” American Journal of Kidney Diseases, vol. 44, no. 1, pp. 57–63, 2004. View at Publisher · View at Google Scholar